Cost of cardiovascular diseases in Serbia
2012
Преузимање 🢃
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’
of mortality, morbidity and economic losses. The aim of this study was to estimate
the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS:
For the purpose of the study CVD was defined by the International Classification of
Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis-
ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence,
top-down method was used to quantify the annual cardiovascular costs. Produc-
tivity losses were estimated using the human capital approach and the friction cost
method. Data were collected from Serbian Health Insurance Fund and National
Public Health Institute “Batut”. A discount rate of 5% was used to convert all future
lifetime earnings into the present value. RESULTS: The total direct costs of CVD in
2009 were € 400 million. The majority of total costs (€ 514.3 million) were for:
medica...tion (29.94%), hospital days (28.97%) and hospital inpatient care — surgical
and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac-
counted for 22.15% of total costs. The results showed that more than half a million
working days were lost due to incapacity resulting from CVDs. The results were
robust to a change in 20% of volume or the unit price of all direct and indirect cost
and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre-
sented approximately 1.8% of the Serbian gross domestic product. The results of
study would be valuable to health policy makers to bridge the gap between in-
vested resources and needs, in order to improve cardiovascular disease outcomes.
Извор:
Value in Health, 2012, 15, 7, A367-A367Издавач:
- Elsevier Inc.
Напомена:
- Research poster presentations – session II
- Disease-specific studies: Cardiovascular disorders - cost studies
- ISPOR 15th Annual European Congress and ISPOR 5th Asia-Pacific Conference
Институција/група
PharmacyTY - CONF AU - Lakić, Dragana AU - Tasić, Ljiljana AU - Kos, Mitja AU - Odalović, Marina AU - Tadić, Ivana PY - 2012 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1684 AB - OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’ of mortality, morbidity and economic losses. The aim of this study was to estimate the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS: For the purpose of the study CVD was defined by the International Classification of Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis- ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence, top-down method was used to quantify the annual cardiovascular costs. Produc- tivity losses were estimated using the human capital approach and the friction cost method. Data were collected from Serbian Health Insurance Fund and National Public Health Institute “Batut”. A discount rate of 5% was used to convert all future lifetime earnings into the present value. RESULTS: The total direct costs of CVD in 2009 were € 400 million. The majority of total costs (€ 514.3 million) were for: medication (29.94%), hospital days (28.97%) and hospital inpatient care — surgical and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac- counted for 22.15% of total costs. The results showed that more than half a million working days were lost due to incapacity resulting from CVDs. The results were robust to a change in 20% of volume or the unit price of all direct and indirect cost and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre- sented approximately 1.8% of the Serbian gross domestic product. The results of study would be valuable to health policy makers to bridge the gap between in- vested resources and needs, in order to improve cardiovascular disease outcomes. PB - Elsevier Inc. C3 - Value in Health T1 - Cost of cardiovascular diseases in Serbia VL - 15 IS - 7 SP - A367 EP - A367 DO - 10.1016/j.jval.2012.08.974 ER -
@conference{ author = "Lakić, Dragana and Tasić, Ljiljana and Kos, Mitja and Odalović, Marina and Tadić, Ivana", year = "2012", abstract = "OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’ of mortality, morbidity and economic losses. The aim of this study was to estimate the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS: For the purpose of the study CVD was defined by the International Classification of Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis- ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence, top-down method was used to quantify the annual cardiovascular costs. Produc- tivity losses were estimated using the human capital approach and the friction cost method. Data were collected from Serbian Health Insurance Fund and National Public Health Institute “Batut”. A discount rate of 5% was used to convert all future lifetime earnings into the present value. RESULTS: The total direct costs of CVD in 2009 were € 400 million. The majority of total costs (€ 514.3 million) were for: medication (29.94%), hospital days (28.97%) and hospital inpatient care — surgical and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac- counted for 22.15% of total costs. The results showed that more than half a million working days were lost due to incapacity resulting from CVDs. The results were robust to a change in 20% of volume or the unit price of all direct and indirect cost and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre- sented approximately 1.8% of the Serbian gross domestic product. The results of study would be valuable to health policy makers to bridge the gap between in- vested resources and needs, in order to improve cardiovascular disease outcomes.", publisher = "Elsevier Inc.", journal = "Value in Health", title = "Cost of cardiovascular diseases in Serbia", volume = "15", number = "7", pages = "A367-A367", doi = "10.1016/j.jval.2012.08.974" }
Lakić, D., Tasić, L., Kos, M., Odalović, M.,& Tadić, I.. (2012). Cost of cardiovascular diseases in Serbia. in Value in Health Elsevier Inc.., 15(7), A367-A367. https://doi.org/10.1016/j.jval.2012.08.974
Lakić D, Tasić L, Kos M, Odalović M, Tadić I. Cost of cardiovascular diseases in Serbia. in Value in Health. 2012;15(7):A367-A367. doi:10.1016/j.jval.2012.08.974 .
Lakić, Dragana, Tasić, Ljiljana, Kos, Mitja, Odalović, Marina, Tadić, Ivana, "Cost of cardiovascular diseases in Serbia" in Value in Health, 15, no. 7 (2012):A367-A367, https://doi.org/10.1016/j.jval.2012.08.974 . .